| Accession |
PRJCA013293 |
| Title |
A phase III study to evaluate the efficacy and safety of sintilimab or placebo combined chemotherapy in subjects with First-line esophagus cancer |
| Relevance |
Medical |
| Data types |
Biomarker
|
| Organisms |
Homo sapiens
|
| Description |
This study is a Randomized, double-blind,multicenter, phase III study to evaluate the efficacy and safety of recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) or placebo combined chemotherapy in subjects with Unresectable, Locally Advanced recurrence or Metastatic First-line esophagus cancer. The primary endpoints are Overall Survival(OS) of the Intention to treat(ITT) crowd; OS of PD-L1 positive subjects in the ITT crowd. |
| Sample scope |
Multiisolate |
| Release date |
2024-11-17 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Innovent
|
|
NA
|
A Randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) or placebo combined chemotherapy in subjects with Unresectable, Locally Advanced recurrence or Metastatic First-line esophagus cancer
|
|
|
| External link |
|
| Submitter |
Lili
Tan (lili.tan@innoventbio.com)
|
| Organization |
Innovent Biologics (Suzhou) Co.,Ltd. |
| Submission date |
2022-11-17 |
